Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019 - 05/12/20
, Kyla N. Price, BS b, Muskaan Sachdeva, BHSc c, Monica Shah, BSc c, Vivian Shi, MD d, Iltefat Hamzavi, MD a, Afsaneh Alavi, MD, MSc, FRCPC e, Michelle A. Lowes, MBBS, PhD fAbstract |
The Fourth Annual Symposium on Hidradenitis Suppurativa (SHSA) took place on November 1-3, 2019, at the Westin Book Cadillac Hotel in Detroit, Michigan. This symposium was a joint meeting of the US Hidradenitis Suppurativa Foundation and the Canadian Hidradenitis Suppurativa Foundation. This cross-disciplinary meeting with experts from around the world was an opportunity to discuss the most recent advances in the study of hidradenitis suppurativa (HS) pathogenesis, clinical trials, classification, scoring systems, complementary/alternative medical treatments, diet, pain management, surgical and laser treatment, and ultrasonographic assessment. A special preconference workshop was held on the use of neodymium-doped yttrium-aluminum-garnet laser hair reduction, sinus tract deroofing, and carbon dioxide laser excision with ultrasonographic mapping and tumescent anesthesia for the treatment of HS. The focused workshops on establishing an HS clinic, setting up an HS support group, the Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository, and wound care were held during the meeting. A special program called HS Ambassadors was established for patients who may have questions about the conference presentations, and in addition, a meet and greet for patients and HS Ambassadors was arranged. To facilitate networking between those early in their careers and clinical and research experts, a mentoring reception was held.
Le texte complet de cet article est disponible en PDF.Key words : CAM, clinical trials, CO2 laser, dermcidin, epigenetics, fibroblasts, hidradenitis suppurativa, HISTORIC, Hidradenitis Suppurativa Core Outcomes Set International Collaboration, HS PROGRESS, IDEOM, interleukins, medical cannabis, metabolome, microbiome, Nd:YAG, pain management, sinus tracts, THESEUS, wound care
Abbreviations used : AAA, BMI, COPD, CO2, HISTORIC, HS, HS PROGRESS, HSCAPS-1, IL, miRNA, Nd:YAG, NSAID, PHQ, QOL, SHSA
Plan
| Drs Alavi and Lowes contributed equally to this article. |
|
| Funding sources: Supported by the Hidradenitis Suppurativa Foundation. |
|
| Disclosure: Dr Shi is a stock shareholder of Learn Health and Altus Lab and has been an advisory board member, investigator, and/or research funding recipient with Sanofi Genzyme, Regeneron, AbbVie, Eli Lilly, Novartis, Sun Pharma, LEO Pharma, Pfizer, Menlo Therapeutics, Burt's Bees, GpSkin, and Skin Actives Scientific. Dr Lowes has served on the advisory board for AbbVie and Janssen and as a consultant for AbbVie, XBiotech, BSN, Kymera, Almirall, and Incyte, unrelated to this manuscript. Dr Hamzavi is an investigator for Unigen Inc, Allergan, Clinuvel, Galderma, L'Oréal, PCORI, Pfizer, Incyte Corporation, Bayer, Estée Lauder, Ferndale Healthcare Inc, Lenicura, General Electric, Janssen Biotech, and Johnson & Johnson; is the cochair of the Global Vitiligo Foundation (unpaid); is on the AbbVie advisory board (unpaid); is president of the Hidradenitis Suppurativa Foundation; and is a subinvestigator for Bristol Myers Squibb and for Merck/MK-3200-011. Dr Alavi has consulted for AbbVie, Janssen, LEO, Galderma, Novartis, Valeant, Kymera, Eli Lily, and InflaRx; is an investigator for AbbVie, Novartis, Regeneron, Pfizer, Boehringer Ingelheim, Glenmark, Merck Serono, Roche, Xoma, UCB, InflaRx, Janssen, Novartis, Dermavant, and Xenon; and received an unrestricted educational grant from AbbVie. Dr Narla and Authors Price, Sachdeva, and Shah have no conflicts of interest to declare. |
|
| IRB approval status: Not applicable. |
|
| Reprints not available from the authors. |
Vol 84 - N° 1
P. 120-129 - janvier 2021 Retour au numéro
Article précédent
- Reflectance confocal microscopy terminology glossary for melanocytic skin lesions: A systematic review
- Cristian Navarrete-Dechent, Konstantinos Liopyris, Jilliana Monnier, Saud Aleissa, Lindsay M. Boyce, Caterina Longo, Margaret Oliviero, Harold Rabinovitz, Ashfaq A. Marghoob, Allan C. Halpern, Giovanni Pellacani, Alon Scope, Manu Jain
- Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis
- Nikolai Loft, Anne-Sofie Halling, Alexander Egeberg, Lone Skov
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?